← brief for 2026-08-15 · Slowing decline

GLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.

Article B Peer reviewed Small trial

Key takeaways

This study of 153,412 adults with- or without Alzheimer's risk factors found GLP-1 drugs reduce risk of Alzheimer's and cardiorenal events. The study used federated EHR data from 29 million patients.

Who did this work

Murugadoss K · Venkatakrishnan AJ · Soundararajan V

Source

Article · PubMed, the drug frontier · 2026 Aug 3
https://pubmed.ncbi.nlm.nih.gov/42602880/